APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics and Biosimilars

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

Selected research

Market Outlook & Growth Opportunities

Global Biologics and Biosimilars Market Outlook and Growth Opportunities 2026

25 December 2025204 pages

Choose your research edition.

Industry ResearchBiologics and Biosimilars Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics and Biosimilars Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics and Biosimilars Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics and Biosimilars Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

The major global manufacturers of biologics and biosimilars are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Sansheng Pharmaceuticals, Changchun Gaoxin, CITICS Guojia, Baitai Biotech, Sijin Biotech, Cinda Biotech, Tonghua Dongbao, Ganli and Union Pharmaceuticals, etc. Roche, Amgen and AbbVie are the top three, with a combined market share of about 37%.

Read the full market overview

This report provides an overview of the global Biologics and Biosimilars market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biologics and Biosimilars and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biologics and Biosimilars sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biologics and Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Biologics and Biosimilars Segment by Company

Roche

Amgen

AbbVie

Sanofi-Aventis

Johnson & Johnson

Pfizer

Novo Nordisk

Eli Lilly

Novartis

Merck

3sbio

Changchun High Tech

CP Guojian

Biotech

Gelgen

Innovent

Dong Bao

Ganlee

United Laboratories

Biologics and Biosimilars Segment by Type

Monoclonal Antibodies

Interferon

Erythropoietin

Insulin

Vaccines

Others

Biologics and Biosimilars Segment by Application

Tumor

Diabetes

Cardiovascular

Hemophilia

Others

Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biologics and Biosimilars status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Biologics and Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biologics and Biosimilars significant trends, drivers, influence factors in global and regions.

6. To analyze Biologics and Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biologics and Biosimilars market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics and Biosimilars industry.

Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Biologics and Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biologics and Biosimilars Industry Trends Table 2. Biologics and Biosimilars Industry Drivers Table 3. Biologics and Biosimilars Industry Opportunities and Challenges Table 4. Biologics and Biosimilars Industry Restraints Table 5. Global Biologics and Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biologics and Biosimilars Revenue Share by Company (2021-2026) Table 7. Global Biologics and Biosimilars Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Biologics and Biosimilars Sales Volume Share by Company (2021-2026) Table 9. Global Biologics and Biosimilars Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Biologics and Biosimilars Company Ranking, (2024-2026) & (USD Million) Table 11. Global Biologics and Biosimilars Key Company Manufacturing Base & Headquarters Table 12. Global Biologics and Biosimilars Company, Product Type & Application Table 13. Global Biologics and Biosimilars Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Monoclonal Antibodies Table 18. Significant Companies of Interferon Table 19. Significant Companies of Erythropoietin Table 20. Significant Companies of Insulin Table 21. Significant Companies of Vaccines Table 22. Significant Companies of Others Table 23. Global Biologics and Biosimilars Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Biologics and Biosimilars Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Biologics and Biosimilars Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Biologics and Biosimilars Sales Volume Share by Type (2021-2026) Table 27. Global Biologics and Biosimilars Sales Volume Share by Type (2027-2032) Table 28. Global Biologics and Biosimilars Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Biologics and Biosimilars Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Biologics and Biosimilars Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Biologics and Biosimilars Sales Value Share by Type (2021-2026) Table 32. Global Biologics and Biosimilars Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Tumor Table 34. Significant Companies of Diabetes Table 35. Significant Companies of Cardiovascular Table 36. Significant Companies of Hemophilia Table 37. Significant Companies of Others Table 38. Global Biologics and Biosimilars Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Biologics and Biosimilars Sales Volume by Application (2021-2026) & (K Units) Table 40. Global Biologics and Biosimilars Sales Volume by Application (2027-2032) & (K Units) Table 41. Global Biologics and Biosimilars Sales Volume Share by Application (2021-2026) Table 42. Global Biologics and Biosimilars Sales Volume Share by Application (2027-2032) Table 43. Global Biologics and Biosimilars Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Biologics and Biosimilars Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Biologics and Biosimilars Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Biologics and Biosimilars Sales Value Share by Application (2021-2026) Table 47. Global Biologics and Biosimilars Sales Value Share by Application (2027-2032) Table 48. Global Biologics and Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 49. Global Biologics and Biosimilars Sales by Region (2021-2026) & (K Units) Table 50. Global Biologics and Biosimilars Sales Market Share by Region (2021-2026) Table 51. Global Biologics and Biosimilars Sales by Region (2027-2032) & (K Units) Table 52. Global Biologics and Biosimilars Sales Market Share by Region (2027-2032) Table 53. Global Biologics and Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Biologics and Biosimilars Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Biologics and Biosimilars Sales Value Share by Region (2021-2026) Table 56. Global Biologics and Biosimilars Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Biologics and Biosimilars Sales Value Share by Region (2027-2032) Table 58. Global Biologics and Biosimilars Market Average Price (USD/Unit) by Region (2021-2026) Table 59. Global Biologics and Biosimilars Market Average Price (USD/Unit) by Region (2027-2032) Table 60. Global Biologics and Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. Global Biologics and Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 63. Global Biologics and Biosimilars Sales Market Share by Country (2021-2026) Table 64. Global Biologics and Biosimilars Sales by Country (2027-2032) & (K Units) Table 65. Global Biologics and Biosimilars Sales Market Share by Country (2027-2032) Table 66. Global Biologics and Biosimilars Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Biologics and Biosimilars Sales Value Market Share by Country (2021-2026) Table 68. Global Biologics and Biosimilars Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Biologics and Biosimilars Sales Value Market Share by Country (2027-2032) Table 70. Roche Company Information Table 71. Roche Business Overview Table 72. Roche Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 73. Roche Biologics and Biosimilars Product Portfolio Table 74. Roche Recent Development Table 75. Amgen Company Information Table 76. Amgen Business Overview Table 77. Amgen Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 78. Amgen Biologics and Biosimilars Product Portfolio Table 79. Amgen Recent Development Table 80. AbbVie Company Information Table 81. AbbVie Business Overview Table 82. AbbVie Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 83. AbbVie Biologics and Biosimilars Product Portfolio Table 84. AbbVie Recent Development Table 85. Sanofi-Aventis Company Information Table 86. Sanofi-Aventis Business Overview Table 87. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 88. Sanofi-Aventis Biologics and Biosimilars Product Portfolio Table 89. Sanofi-Aventis Recent Development Table 90. Johnson & Johnson Company Information Table 91. Johnson & Johnson Business Overview Table 92. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Johnson & Johnson Biologics and Biosimilars Product Portfolio Table 94. Johnson & Johnson Recent Development Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 98. Pfizer Biologics and Biosimilars Product Portfolio Table 99. Pfizer Recent Development Table 100. Novo Nordisk Company Information Table 101. Novo Nordisk Business Overview Table 102. Novo Nordisk Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 103. Novo Nordisk Biologics and Biosimilars Product Portfolio Table 104. Novo Nordisk Recent Development Table 105. Eli Lilly Company Information Table 106. Eli Lilly Business Overview Table 107. Eli Lilly Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 108. Eli Lilly Biologics and Biosimilars Product Portfolio Table 109. Eli Lilly Recent Development Table 110. Novartis Company Information Table 111. Novartis Business Overview Table 112. Novartis Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 113. Novartis Biologics and Biosimilars Product Portfolio Table 114. Novartis Recent Development Table 115. Merck Company Information Table 116. Merck Business Overview Table 117. Merck Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 118. Merck Biologics and Biosimilars Product Portfolio Table 119. Merck Recent Development Table 120. 3sbio Company Information Table 121. 3sbio Business Overview Table 122. 3sbio Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 123. 3sbio Biologics and Biosimilars Product Portfolio Table 124. 3sbio Recent Development Table 125. Changchun High Tech Company Information Table 126. Changchun High Tech Business Overview Table 127. Changchun High Tech Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 128. Changchun High Tech Biologics and Biosimilars Product Portfolio Table 129. Changchun High Tech Recent Development Table 130. CP Guojian Company Information Table 131. CP Guojian Business Overview Table 132. CP Guojian Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 133. CP Guojian Biologics and Biosimilars Product Portfolio Table 134. CP Guojian Recent Development Table 135. Biotech Company Information Table 136. Biotech Business Overview Table 137. Biotech Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 138. Biotech Biologics and Biosimilars Product Portfolio Table 139. Biotech Recent Development Table 140. Gelgen Company Information Table 141. Gelgen Business Overview Table 142. Gelgen Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 143. Gelgen Biologics and Biosimilars Product Portfolio Table 144. Gelgen Recent Development Table 145. Innovent Company Information Table 146. Innovent Business Overview Table 147. Innovent Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 148. Innovent Biologics and Biosimilars Product Portfolio Table 149. Innovent Recent Development Table 150. Dong Bao Company Information Table 151. Dong Bao Business Overview Table 152. Dong Bao Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 153. Dong Bao Biologics and Biosimilars Product Portfolio Table 154. Dong Bao Recent Development Table 155. Ganlee Company Information Table 156. Ganlee Business Overview Table 157. Ganlee Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 158. Ganlee Biologics and Biosimilars Product Portfolio Table 159. Ganlee Recent Development Table 160. United Laboratories Company Information Table 161. United Laboratories Business Overview Table 162. United Laboratories Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 163. United Laboratories Biologics and Biosimilars Product Portfolio Table 164. United Laboratories Recent Development Table 165. Key Raw Materials Table 166. Raw Materials Key Suppliers Table 167. Biologics and Biosimilars Distributors List Table 168. Biologics and Biosimilars Customers List Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Biologics and Biosimilars Product Image Figure 2. Global Biologics and Biosimilars Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 4. Global Biologics and Biosimilars Sales (2021-2032) & (K Units) Figure 5. Global Biologics and Biosimilars Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Biologics and Biosimilars Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Monoclonal Antibodies Image Figure 10. Interferon Image Figure 11. Erythropoietin Image Figure 12. Insulin Image Figure 13. Vaccines Image Figure 14. Others Image Figure 15. Global Biologics and Biosimilars Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Biologics and Biosimilars Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Biologics and Biosimilars Sales Volume Share by Type (2021-2032) Figure 18. Global Biologics and Biosimilars Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Biologics and Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Biologics and Biosimilars Sales Value Share by Type (2021-2032) Figure 21. Tumor Image Figure 22. Diabetes Image Figure 23. Cardiovascular Image Figure 24. Hemophilia Image Figure 25. Others Image Figure 26. Global Biologics and Biosimilars Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Biologics and Biosimilars Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Biologics and Biosimilars Sales Volume Share by Application (2021-2032) Figure 29. Global Biologics and Biosimilars Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Biologics and Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Biologics and Biosimilars Sales Value Share by Application (2021-2032) Figure 32. Global Biologics and Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 33. Global Biologics and Biosimilars Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Biologics and Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Biologics and Biosimilars Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 37. North America Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 43. South America Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Biologics and Biosimilars Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Biologics and Biosimilars Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Interferon
  • Erythropoietin
  • Insulin
  • Vaccines
  • Others
Applications
  • Tumor
  • Diabetes
  • Cardiovascular
  • Hemophilia
  • Others
Companies covered
  • Roche
  • Amgen
  • AbbVie
  • Sanofi-Aventis
  • Johnson & Johnson
  • Pfizer
  • Novo Nordisk
  • Eli Lilly
  • Novartis
  • Merck
  • 3sbio
  • Changchun High Tech
  • CP Guojian
  • Biotech
  • Gelgen
  • Innovent
  • Dong Bao
  • Ganlee
  • United Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biologics and Biosimilars Sales Value (2021-2032)
  4. 1.2.2 Global Biologics and Biosimilars Sales Volume (2021-2032)
  5. 1.2.3 Global Biologics and Biosimilars Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Biologics and Biosimilars Market Dynamics
  1. 2.1 Biologics and Biosimilars Industry Trends
  2. 2.2 Biologics and Biosimilars Industry Drivers
  3. 2.3 Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Biologics and Biosimilars Industry Restraints
3 Biologics and Biosimilars Market by Company
  1. 3.1 Global Biologics and Biosimilars Company Revenue Ranking in 2025
  2. 3.2 Global Biologics and Biosimilars Revenue by Company (2021-2026)
  3. 3.3 Global Biologics and Biosimilars Sales Volume by Company (2021-2026)
  4. 3.4 Global Biologics and Biosimilars Average Price by Company (2021-2026)
  5. 3.5 Global Biologics and Biosimilars Company Ranking (2024-2026)
  6. 3.6 Global Biologics and Biosimilars Company Manufacturing Base and Headquarters
  7. 3.7 Global Biologics and Biosimilars Company Product Type and Application
  8. 3.8 Global Biologics and Biosimilars Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Biologics and Biosimilars Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Biologics and Biosimilars Market by Type
  1. 4.1 Biologics and Biosimilars Type Introduction
  2. 4.1.1 Monoclonal Antibodies
  3. 4.1.2 Interferon
  4. 4.1.3 Erythropoietin
  5. 4.1.4 Insulin
  6. 4.1.5 Vaccines
  7. 4.1.6 Others
  8. 4.2 Global Biologics and Biosimilars Sales Volume by Type
  9. 4.2.1 Global Biologics and Biosimilars Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Biologics and Biosimilars Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Biologics and Biosimilars Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Biologics and Biosimilars Sales Value by Type
  13. 4.3.1 Global Biologics and Biosimilars Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Biologics and Biosimilars Sales Value by Type (2021-2032)
  15. 4.3.3 Global Biologics and Biosimilars Sales Value Share by Type (2021-2032)
5 Biologics and Biosimilars Market by Application
  1. 5.1 Biologics and Biosimilars Application Introduction
  2. 5.1.1 Tumor
  3. 5.1.2 Diabetes
  4. 5.1.3 Cardiovascular
  5. 5.1.4 Hemophilia
  6. 5.1.5 Others
  7. 5.2 Global Biologics and Biosimilars Sales Volume by Application
  8. 5.2.1 Global Biologics and Biosimilars Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Biologics and Biosimilars Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Biologics and Biosimilars Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Biologics and Biosimilars Sales Value by Application
  12. 5.3.1 Global Biologics and Biosimilars Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Biologics and Biosimilars Sales Value by Application (2021-2032)
  14. 5.3.3 Global Biologics and Biosimilars Sales Value Share by Application (2021-2032)
6 Biologics and Biosimilars Regional Sales and Value Analysis
  1. 6.1 Global Biologics and Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biologics and Biosimilars Sales by Region (2021-2032)
  3. 6.2.1 Global Biologics and Biosimilars Sales by Region: 2021-2026
  4. 6.2.2 Global Biologics and Biosimilars Sales by Region (2027-2032)
  5. 6.3 Global Biologics and Biosimilars Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Biologics and Biosimilars Sales Value by Region (2021-2032)
  7. 6.4.1 Global Biologics and Biosimilars Sales Value by Region: 2021-2026
  8. 6.4.2 Global Biologics and Biosimilars Sales Value by Region (2027-2032)
  9. 6.5 Global Biologics and Biosimilars Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Biologics and Biosimilars Sales Value (2021-2032)
  12. 6.6.2 North America Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Biologics and Biosimilars Sales Value (2021-2032)
  15. 6.7.2 Europe Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Biologics and Biosimilars Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Biologics and Biosimilars Sales Value (2021-2032)
  21. 6.9.2 South America Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Biologics and Biosimilars Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
7 Biologics and Biosimilars Country-level Sales and Value Analysis
  1. 7.1 Global Biologics and Biosimilars Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biologics and Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Biologics and Biosimilars Sales by Country (2021-2032)
  4. 7.3.1 Global Biologics and Biosimilars Sales by Country (2021-2026)
  5. 7.3.2 Global Biologics and Biosimilars Sales by Country (2027-2032)
  6. 7.4 Global Biologics and Biosimilars Sales Value by Country (2021-2032)
  7. 7.4.1 Global Biologics and Biosimilars Sales Value by Country (2021-2026)
  8. 7.4.2 Global Biologics and Biosimilars Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Roche Biologics and Biosimilars Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Amgen
  8. 8.2.1 Amgen Company Information
  9. 8.2.2 Amgen Business Overview
  10. 8.2.3 Amgen Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Biologics and Biosimilars Product Portfolio
  12. 8.2.5 Amgen Recent Developments
  13. 8.3 AbbVie
  14. 8.3.1 AbbVie Company Information
  15. 8.3.2 AbbVie Business Overview
  16. 8.3.3 AbbVie Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AbbVie Biologics and Biosimilars Product Portfolio
  18. 8.3.5 AbbVie Recent Developments
  19. 8.4 Sanofi-Aventis
  20. 8.4.1 Sanofi-Aventis Company Information
  21. 8.4.2 Sanofi-Aventis Business Overview
  22. 8.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
  24. 8.4.5 Sanofi-Aventis Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Biologics and Biosimilars Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Novo Nordisk
  38. 8.7.1 Novo Nordisk Company Information
  39. 8.7.2 Novo Nordisk Business Overview
  40. 8.7.3 Novo Nordisk Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
  42. 8.7.5 Novo Nordisk Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Biologics and Biosimilars Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 Merck
  56. 8.10.1 Merck Company Information
  57. 8.10.2 Merck Business Overview
  58. 8.10.3 Merck Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Merck Biologics and Biosimilars Product Portfolio
  60. 8.10.5 Merck Recent Developments
  61. 8.11 3sbio
  62. 8.11.1 3sbio Company Information
  63. 8.11.2 3sbio Business Overview
  64. 8.11.3 3sbio Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 3sbio Biologics and Biosimilars Product Portfolio
  66. 8.11.5 3sbio Recent Developments
  67. 8.12 Changchun High Tech
  68. 8.12.1 Changchun High Tech Company Information
  69. 8.12.2 Changchun High Tech Business Overview
  70. 8.12.3 Changchun High Tech Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
  72. 8.12.5 Changchun High Tech Recent Developments
  73. 8.13 CP Guojian
  74. 8.13.1 CP Guojian Company Information
  75. 8.13.2 CP Guojian Business Overview
  76. 8.13.3 CP Guojian Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
  78. 8.13.5 CP Guojian Recent Developments
  79. 8.14 Biotech
  80. 8.14.1 Biotech Company Information
  81. 8.14.2 Biotech Business Overview
  82. 8.14.3 Biotech Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Biotech Biologics and Biosimilars Product Portfolio
  84. 8.14.5 Biotech Recent Developments
  85. 8.15 Gelgen
  86. 8.15.1 Gelgen Company Information
  87. 8.15.2 Gelgen Business Overview
  88. 8.15.3 Gelgen Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Gelgen Biologics and Biosimilars Product Portfolio
  90. 8.15.5 Gelgen Recent Developments
  91. 8.16 Innovent
  92. 8.16.1 Innovent Company Information
  93. 8.16.2 Innovent Business Overview
  94. 8.16.3 Innovent Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Innovent Biologics and Biosimilars Product Portfolio
  96. 8.16.5 Innovent Recent Developments
  97. 8.17 Dong Bao
  98. 8.17.1 Dong Bao Company Information
  99. 8.17.2 Dong Bao Business Overview
  100. 8.17.3 Dong Bao Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
  102. 8.17.5 Dong Bao Recent Developments
  103. 8.18 Ganlee
  104. 8.18.1 Ganlee Company Information
  105. 8.18.2 Ganlee Business Overview
  106. 8.18.3 Ganlee Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Ganlee Biologics and Biosimilars Product Portfolio
  108. 8.18.5 Ganlee Recent Developments
  109. 8.19 United Laboratories
  110. 8.19.1 United Laboratories Company Information
  111. 8.19.2 United Laboratories Business Overview
  112. 8.19.3 United Laboratories Biologics and Biosimilars Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
  114. 8.19.5 United Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biologics and Biosimilars Value Chain Analysis
  2. 9.1.1 Biologics and Biosimilars Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biologics and Biosimilars Sales Mode & Process
  6. 9.2 Biologics and Biosimilars Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biologics and Biosimilars Distributors
  9. 9.2.3 Biologics and Biosimilars Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst